The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
myHomecare Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advising Australian Unity on its acquisition of myHomecare Group
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Abacus Health Products, Inc.
![](https://www.greenhill.com/sites/default/files/lang-ca-us.png)
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Starpharma Holdings Limited, patented VivaGel BV® product
![Italy, USA flags](https://www.greenhill.com/sites/default/files/italian-us-flag.png)
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Montserrat Day Hospital Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Common shares and common share purchase warrants in Canopy Growth
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aegerion Pharmaceuticals
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Aralez Pharmaceuticals Inc.
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Clinuvel Pharmaceuticals Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
iNova Pharmaceuticals
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Healthcare Australia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK